Targeted Copper Theranostics (TCT)

Clarity’s SAR Technology platform is leading the way in the development of copper-based theranostics. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 (64Cu) and copper-67 (67Cu) for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market.

The term “perfect pairing” relates to the unique characteristics of the two copper isotopes, 64Cu for diagnosis and 67Cu for therapy, which have been discussed in the scientific literature for approximately 25 years. The pairing is well suited for precision medicine due to the unique physical characteristics of each isotope of copper as well as having the “ideal theranostic pair”, meaning the same product and same element are used for both diagnosis and therapy.

The physical characteristics of 64Cu and 67Cu position this pairing to compete head-to-head with 68Ga and 177Lu and other isotope pairings.

The Perfect Pairing

The term “perfect pairing” relates to the unique characteristics of the two copper isotopes, 64Cu for diagnosis and 67Cu for therapy, which have been discussed in the scientific literature for approximately 25 years. The pairing is well suited for precision medicine due to the unique physical characteristics of each isotope of copper as well as having the “ideal theranostic pair”, meaning the same product and same element are used for both diagnosis and therapy.

The physical characteristics of 64Cu and 67Cu position this pairing to compete head-to-head with 68Ga and 177Lu and other isotope pairings.

Advantages of Cu-64/Cu-67 pairing

Off-site manufacturing

Cu-64 and Cu-67 radiopharmaceuticals are produced centrally under cGMP in the USA. This allows finished products to be supplied directly to hospitals and private treatment centres, reaching more destinations and patients around the world and bringing copper-based theranostics to the larger oncology market.

The radiologic half life of both Cu-64 and Cu-67 is sufficiently long enough to permit offsite/centralised manufacturing. Other currently used radionuclides rely on the prevalent on-site manufacturing model, which requires hospitals to have in-house radiopharmacy capabilities and thus limits the application of the treatments to fewer sites and patients.

No reliance on nuclear reactors

Cu-64 and Cu-67 do not require nuclear reactors to manufacture the isotope, meaning the supply of the radioisotopes is not constrained by a handful of reactors available globally. A significant portion of the world supply of diagnostic and therapeutic radionuclides are produced directly or indirectly on nuclear reactors. Supply issues are frequent and can be caused by a single reactor shutting down.

High accuracy/ high precision theranostic pairing

By utilising chemically identical products for diagnosis and therapy, highly precise and highly accurate targeting of therapeutics can be achieved.